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coronary vasospasm associated with K-CP.1-3 The state
of coronary vasomotor tone may affect not only the dis-
tribution of cardioplegic solution during administration
but also influence the coronary microcirculation in the
postoperative setting.
Ischemic preconditioning has long been recognized to
protect the heart from ischemia/reperfusion injury.4
H yperkalemic cardioplegia (K-CP) is the most wide-ly used technique for myocardial protection during
cardiac operations. Although its effectiveness in pro-
tecting the cardiomyocyte against prolonged ischemia
has been well established, it is frequently imperfect. A
reason for suboptimal myocardial recovery may be
related to reduced myocardial perfusion as the result of
Objectives: The effect of preconditioning before hyperkalemic cardiople-
gia on the coronary smooth muscle remains to be elucidated. We tested
the hypothesis that hypoxic preconditioning could protect coronary
smooth muscle against subsequent hyperkalemic cardioplegia-induced
coronary vasospasm and that this preconditioning effect could be medi-
ated by KATP channels. Methods: Rat coronary arterioles (endothelium-
denuded) were studied in a pressurized, no-flow, normothermic state.
Simultaneous monitoring of luminal diameter and intracellular calcium
concentration of vascular smooth muscle loaded with fura-2 was made
with microscopic image analysis. All vessels were subjected to 60 min-
utes of hypoxic hyperkalemic cardioplegia (K+ = 25.0 mmol/L) and were
then reperfused. Six groups were studied: (1) controls, no precardio-
plegic intervention; (2) preconditioning, achieved with 10 minutes of
hypoxia (PO2 < 30 mm Hg) and 10 minutes of reoxygenation; (3) pre-
conditioning plus glibenclamide (10 m mol/L), achieved with 10 minutes
of preconditioning in the presence of KATP channel blocker gliben-
clamide; (4) pretreatment with KATP channel opener pinacidil (100
m mol/L); (5) pretreatment with pinacidil (100 m mol/L) plus gliben-
clamide (10 m mol/L); and (6) pretreatment with glibenclamide (10
m mol/L) alone. Results: Hypoxic preconditioning significantly (P < .01)
reduced hyperkalemic cardioplegia-induced intracellular calcium con-
centration accumulation and prevented the hypercontractility during
and after hyperkalemic cardioplegia compared with control vessels.
Pinacidil provided effective microvascular protection similar to hypoxic
preconditioning. These vasoprotective effects of preconditioning were
significantly antagonized in glibenclamide-treated vessels. Conclusions:
Hypoxic preconditioning can prevent coronary microvascular hyper-
contractility during and after subsequent cardioplegia by a KATP chan-
nel mechanism that regulates intracellular calcium concentration of the
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There is also clinical evidence that, during percuta-
neous transluminal coronary angioplasty or coronary
bypass grafting, a brief period of ischemia similar to
preconditioning may protect the heart from subsequent
prolonged coronary occlusion and can reduce the inci-
dence of myocardial infarction or severe myocardial
dysfunction.5,6 Recently, some studies have demon-
strated that the combination of ischemic precondition-
ing and cardioplegic arrest improved left ventricular
pump function.7,8
We and others9-11 have recently reported beneficial
effects of preconditioning on endothelial functional
preservation. However, it remains unclear whether the
protective effects of preconditioning also extends to
coronary microvascular smooth muscle in the setting of
K-CP. Similarly, although in a variety of mammalians
including humans there has been accumulating evi-
dence that an activation of adenosine triphosphate–sen-
sitive K+ (KATP) channels plays an important role in
ischemic myocardial preconditioning,12-14 there is less
consensus regarding the involvement of the KATP chan-
nel in the preconditioning phenomenon observed in
coronary microvasculature.
To investigate the vasoprotective mechanisms of pre-
conditioning adjuvant to K-CP, we established an in
vitro isolated coronary microvessel model. Although
this preparation presents interpretive limitations with
regard to the in vivo coronary system, it does provide a
suitable situation in which to perform real-time analyses
of the microvascular tone and intracellular calcium
dynamics in coronary arterioles during K-CP. Thus the
aims of this study were to determine whether hypoxic
preconditioning would limit the extent of cardioplegia-
related coronary vasospasm during and after subsequent
K-CP and, if so, whether activation of KATP channels
plays a role in the preserved microvascular function.
Material and methods
Isolated microvessel preparations. The methods for iso-
lation of coronary microvessels were described previously.1
In brief, male Sprague-Dawley rats weighing between 350
and 400 g were anesthetized with chloroform. Sodium
heparin (1000 IU/kg) was then administered intravenously.
The heart was removed and placed into cold (4°C) Krebs
physiologic saline solution (Krebs-PSS), which consisted of
the following ion concentrations (in millimoles per liter):
NaCl 119.0, NaHCO3 25.0, KCl 4.6, KH2PO4 1.2, MgSO4
1.2, CaCl2 1.8, and glucose 11.0. Coronary arterial microves-
sels (80-130 m m in internal diameter) were dissected from the
left anterior descending artery–dependent subepicardial
region in the left ventricle with a · 10 to · 60 dissecting micro-
scope (Olympus Optical, Tokyo, Japan). During dissection,
care was taken to remove as much of the surrounding
myocardium as possible. The endothelium was removed
selectively by advancement of a human hair (approximately
60 m m in diameter) into the lumen to abrade the luminal sur-
face, followed by the intraluminal injection of air bubbles.
Microvessels were transferred to an experimental chamber in
which both ends of the microvessel were cannulated with
dual glass micropipettes (tip interior diameter, approximately
60 m m) and secured with 10-0 nylon monofilament suture
(Ethicon, Inc, Somerville, NJ). The chamber was mounted on
a transillumination system and oxygenated (95% oxygen/5%
carbon dioxide); Krebs-PSS was continuously circulated
through the tissue chamber. In all experiments, the absence of
functional endothelium was tested by determining the
responses to adenosine 5´-diphosphate (100 m mol/L) and
sodium nitroprusside (100 m mol/L) in microvessels precon-
tracted with U46619 (0.1 m mol/L). All vessels denuded of
endothelium showed complete relaxation to sodium nitro-
prusside but failed to relax in response to adenosine diphos-
phate. All of the animals received humane care in compliance
with the “Guide for the Care and Use of Laboratory Animals”
published by the National Institute of Health (NIH
Publication No. 85-23, revised 1985).
Internal luminal diameter measurements. The vessels
were pressurized to 40 mm Hg in a no-flow state with a
burette manometer filled with Krebs-PSS. The internal lumi-
nal diameter was measured with a microscopic image system
(Zeiss IM35 [Carl Zeiss, Inc, Jena, Germany] and Hitachi CCD
TV camera, model KP-115 [Hitachi Ltd, Tokyo, Japan]). The
calibration of the measurement was performed with an 80-
m m tungsten wire. The minimum resolution of the system
was 1.5 m m.
Intracellular calcium concentration measurement.
Intracellular calcium concentration of coronary microvascu-
lar smooth muscle was measured by the method described  by
Meininger and colleagues.15 Coronary microvessels in the
tissue chamber were loaded with 5 m mol/L acetoxy-
methylester of fura-2 (fura-2/AM) in Krebs-PSS containing
0.05% dimethyl sulfoxide and 0.01% poloxamer (Pluronic F-
127; BASF Corp, Mt Olive, NJ). The loading time was 45
minutes followed by a 30-minute wash period at 37°C. The
objective lens used was a Nikon Fluor · 40 (numerical aper-
ture, 0.8) (Nikon Corp, Tokyo, Japan). Optimal focus was
adjusted to the middle of the vascular smooth muscle layer by
a view of the vascular wall under a bright microscopic field.
Excitation light at 350 ± 5 nm and 390 ± 6 nm was used.
Emission at 510 ± 24 nm was monitored with a photomulti-
plier tube (Hamamatsu R928; Hamamatsu Phonetics KK,
Hamamatsu City, Japan) and digitized by a Data Acquisition-
EZ A/D Converter (Data Translation, Inc, Marlboro, Mass).
The digital signal of the 2 wavelengths was processed by a
program written with the DTVee version 3.0 programming
environment (Data Translation, Inc, Marlboro, Mass).
Intracellular calcium concentration was estimated from the
ratio (R350/390) of measured fluorescence signals (F) elicited
at 2 wavelengths according to the equation:
R350/390 = (F350mv–F350bg)/(F390mv–F390bg) 







are the total measured fluores-
cence of the microvessels at wavelengths of 350 and 390 nm,
and F350bg and F390bg are the background fluorescence sig-
nals at the respective wavelength. The background signals
were measured on microvessel before loading fura-2/AM.
Because there are a number of assumptions and concomitant
uncertainties in absolute intracellular calcium concentration
quantification with fura-2, on both practical and theoretic lev-
els,16 the ratio (R350/390) was used as an index of intracellular
calcium concentration.
Experimental design. In an attempt to simulate the non-
oxygenated crystalloid cardioplegia in the operating room, an
in vitro hypoxic K-CP model was designed. Hypoxia (simu-
lated ischemia) was used in the present study because
ischemia (lack of blood flow) would not be an accurate term
in regard to this continuously superfused microvascular
model. After baseline measurement of intracellular calcium
concentration and internal luminal diameter were taken,
microvessels were subjected to 60 minutes of hypoxic K-CP
of the following composition (in millimoles per liter): 121
NaCl, 25 KCl, 12 NaHCO3, 1.2 CaCl2, and 11.1 glucose and
then reperfused with oxygenated Krebs-PSS for 60 minutes.
Hypoxic condition was induced by switching bubbling gas
from 95% oxygen/5% carbon dioxide to 95% nitrogen/5%
carbon dioxide. The partial pressure of oxygen (PO2) in the
hypoxic K-CP reached a stable level below 30 mm Hg with-
in 2 minutes after changing the bubbling gas. True anoxic
condition was not achieved because a small amount of oxy-
gen continuously diffused into the K-CP from the atmos-
phere. The pH was 7.4 ± 0.1, and PCO2 was 35 ± 5 mm Hg.
The temperature was maintained at 37°C throughout the
experiments.
Experimental protocols. The experimental protocols are
depicted in Fig 1. Six groups were studied: (1) control, no
pre–K-CP intervention; (2) preconditioning, achieved with
10 minutes of hypoxia in Krebs-PSS followed by 10 minutes
of reoxygenation before the exposure of prolonged hypoxic
K-CP; (3) preconditioning plus glibenclamide, achieved with
preconditioning in the presence of KATP channel blocker
glibenclamide (10 m mol/L) before K-CP; (4) pinacidil,
achieved by pretreatment with KATP channel opener pinacidil
(100 m mol/L) before K-CP; (5) pinacidil plus glibenclamide,
achieved by pretreatment with pinacidil (100 m mol/L) in the
presence of glibenclamide (10 m mol/L) before K-CP; and (6)
glibenclamide alone, achieved by pretreatment with gliben-
clamide (10 m mol/L) before K-CP.
Evaluation of microvascular function. After 60 minutes of
reoxygenation, a cumulative concentration-response curve to a
stable thromboxane A2 analogue, U46619 (10–9 -10–6 mol/L)
was constructed to evaluate the agonist-induced vascular con-
tractility. Finally, papaverine (100 m mol/L) was applied in the
tissue chamber to normalize the vascular diameter.
Drugs. Fura-2/AM and Pluronic F-127 were obtained from
Molecular Probes (Eugene, Ore). Pinacidil was obtained from
Research Biochemical International (Natick, Mass).
Glibenclamide and U46619 were purchased from Sigma
Chemical Company (St Louis, Mo). Papaverine was obtained
from Eli Lilly & Co (Indianapolis, Ind). Glibenclamide and
pinacidil were dissolved in dimethyl sulfoxide initially and then
added to the Krebs-PSS. The final concentration of dimethyl
sulfoxide in the experimental solutions did not exceed 0.1%.
Statistical analysis. The response of microvessels to each
intervention was examined only once in each animal.
Therefore each animal served as one sample. The changes in
internal luminal diameter were expressed as percent contrac-
tion of the normalized diameter with application of papaver-
ine. Results are expressed as mean ± SD. The paired Student
t test was applied for within-group comparisons with base-
line. Analysis of variance combined with a multiple-compar-
ison Fisher’s test was used to test the differences among
groups with different interventions (StatView 4.0; Abacus
Concepts Inc, Berkeley, Calif).
Results
Baseline characteristics before K-CP. Baseline
measurements taken before the exposure to K-CP are
shown in Table I. Among the 6 groups, there were no
significant differences in the baseline contraction and
intracellular calcium concentration of microvascular
smooth muscle, which suggests that each pretreatment
protocol used in the present study did not cause signif-
icant changes in the steady-state microvascular tone.
Microvascular responses during K-CP. Fig 2
shows the representative time-course changes in vascu-
Fig 1. Schematic diagram of the experimental protocols. PC,
Preconditioning; PC+GLIB, preconditioning in the presence
of glibenclamide (10 m mol/L); PIN, pretreatment with
pinacidil (100 m mol/L); PIN+GLIB, pretreatment with
pinacidil (100 m mol/L) plus glibenclamide (10 m mol/L);
GLIB, pretreatment with glibenclamide (10 m mol/L) alone;
BL, baseline measurements.
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lar contraction and intracellular calcium concentration
during and after K-CP. In all vessels, vascular contrac-
tion increased gradually in a time-dependent manner,
and these changes in vascular contraction were associ-
ated with changes in intracellular calcium concentra-
tion. After reperfusion, the vascular diameter and intra-
cellular calcium concentration returned to baseline
levels within approximately 15 minutes in all vessels.
To clarify the effects of each preconditioning proto-
col on the K-CP–induced vascular contraction, we
focused on the responses at the end of 60 minutes of the
K-CP period (Fig 3). All vessels in the 6 groups exhib-
ited significant increases both in vascular contraction
and intracellular calcium concentration compared with
respective baseline level (P < .001). Hypoxic precondi-
tioning caused a significant decrease both in the K-
CP–induced vascular contraction and intracellular cal-
cium concentration elevation compared with control
vessels (percent contraction, 25.2% ± 5.8% vs 36.2% ±
5.9%; intracellular calcium concentration, 0.61 ± 0.05
vs 0.74 ± 0.06 in preconditioning vs control vessels,
respectively; both P < .01). Furthermore, pinacidil pre-
treatment significantly reduced the K-CP–induced vas-
cular contraction and intracellular calcium concentra-
tion elevation (percent contraction, 22.6% ± 3.3%;
intracellular calcium concentration, 0.62 ± 0.04; both P
< .01 vs control). In marked contrast, coadministration
of the KATP channel blocker glibenclamide completely
reversed the effects of hypoxic preconditioning or
pinacidil pretreatment. Pretreatment with gliben-
clamide alone did not exert significant effects on the K-
CP–induced vascular contraction and intracellular cal-
cium concentration elevation compared with control
group. These observations indicate that hypoxic pre-
conditioning can attenuate K-CP–induced vascular
contraction through a KATP channel mechanism, which
reduces intracellular calcium concentration accumula-
tion in coronary smooth muscle.
Microvascular function after K-CP/reperfusion.
The data presented in Fig 4 illustrate the agonist-
induced contractile responses to U46619 at the end of
60 minutes of reperfusion. A separate group (n = 8) of
rats were used to measure normal contractility (base-
line response) of vessels not exposed to K-CP. U46619-
evoked vessel contractility was significantly enhanced
in control and the 3 glibenclamide-administered groups
compared with the baseline response (all P < .05). On
hypoxic preconditioned or pinacidil-pretreated vessels,
vascular contractility elicited by U46619 was entirely
preserved in a baseline response level. The results sug-
Table I. Baseline values of internal luminal diameter
and intracellular calcium concentration in coronary
microvessels
Intracellular 
Diameter calcium concentration 
n (%) (R350/390)
Control 8 96.2 ± 4.6 0.42 ± 0.04
PC 8 97.3 ± 5.3 0.41 ± 0.04
PC+GLIB 8 95.7 ± 5.5 0.43 ± 0.03
PIN 8 97.5 ± 5.0 0.42 ± 0.04
PIN+GLIB 6 98.0 ± 3.7 0.43 ± 0.05
GLIB 6 96.8 ± 4.2 0.42 ± 0.04
Microvascular diameter was expressed as percentage of normalized diameter
with papaverine (100 m mol/L). Intracellular calcium concentration was mea-
sured with fura-2 and expressed as the ratio of fluorescent signals at 350 and
390 nm (R350/390). All values are shown as mean ± SD. (See Fig 1 for group
definitions.) There was no significant difference between groups (all P > .2).
Fig 2. Representative time course profiles during and after K-
CP in (A) vascular contraction and (B) intracellular calcium
concentration ([Ca2+]i) in vascular smooth muscle.
Contractile responses were expressed as percent contraction
of normalized diameter with papaverine (100 m mol/L).
Intracellular calcium concentration was measured by fura-2
and expressed as the fluorescent ratio of F350/F390. (See Fig
1 for group definitions.)
A
B
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gest that hypoxic preconditioning or pinacidil pretreat-
ment preserved physiologic level of agonist-induced
vascular contractility after K-CP/reperfusion.
Discussion
The unique findings of this study were 2-fold. First,
hypoxic preconditioning reduced the intracellular cal-
cium concentration accumulation in coronary vascular
smooth muscle and attenuated the vascular contraction
during subsequent hypoxic K-CP and prevented
microvascular smooth muscle hypercontractility after
K-CP/reperfusion. Second, this protective effect of
hypoxic preconditioning can be mimicked by pharma-
cologic activation of KATP channels with pinacidil.
Effect of hypoxic preconditioning on K-CP–
induced vascular contraction. Ischemic precondition-
ing refers to the observation that brief periods of
ischemia and reperfusion protect the myocardium from
injury during subsequent more severe ischemic insults.4
This phenomenon has been described in a number of
species. It has been known that preconditioning stimuli
are species specific. In this study, we used rat heart
because preconditioning has been shown to confer
myocardial functional protection in this species.17,18
Several recent studies have demonstrated that the
beneficial effect of preconditioning is not limited to the
cardiomyocytes but can be observed in endothelial
cells in various experimental models, including dog
resistance coronary arteries in vivo10 and conduit coro-
nary arteries of the rat in vitro.11 We have already
reported that temporary ischemia/reperfusion before
prolonged ischemia could preserve endothelial func-
tion in pig coronary microvessels9; however, whether
the microvascular smooth muscle of the coronaries is
included in the preconditioning phenomenon remains
A
B
Fig 3. Comparisons in (A) vascular contraction and (B) intra-
cellular calcium concentration ([Ca2+]i) in vascular smooth
muscle at the end of 60 minutes of K-CP. Contractile respons-
es were expressed as percent contraction of normalized diam-
eter with papaverine (100 m mol/L). Intracellular calcium con-
centration was measured by fura-2 and expressed as the
fluorescent ratio of F350/F390. All values are shown as
means ± SD. (See Fig 1 for group definitions.) Statistically
significant P values are given.
Fig 4. Concentration-response curve to receptor-mediated
vasoconstrictor U46619 after K-CP and reperfusion. Con-
tractile responses were expressed as percent contraction of
normalized diameter with papaverine (100 m mol/L). All val-
ues are shown as means ± SD. (See Fig 1 for group defini-
tions.) Baseline, Baseline response, vessels not exposed to
hypoxic K-CP. aP < .05 vs Baseline; bP < .05 vs PC; cP = .02
vs PIN.
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unresolved. Such distinction between endothelium and
vascular smooth muscle would be essential to under-
stand the precise nature of vascular preconditioning
phenomenon. Therefore we used an endothelium-
denuded rat coronary microvessel model to investigate
vascular smooth muscle response to hypoxic precondi-
tioning in conditions of simulated hyperkalemic car-
dioplegic arrest in cardiac operations. Our results
demonstrated that preconditioning was able to attenu-
ate the coronary smooth muscle hypercontractility
associated with hypoxic K-CP.
In the present study, we examined intracellular calci-
um concentration in vascular smooth muscle to investi-
gate the cellular and molecular mechanisms of the vas-
cular preconditioning phenomenon against K-CP–
induced vascular contraction. Our experiments with
hypoxic preconditioning clearly show that attenuation
of the K-CP–induced contraction is associated with a
decrease in calcium concentration accumulation in vas-
cular smooth muscle. This suggests that hypoxic pre-
conditioning profoundly influences the intracellular
calcium concentration regulation systems in vascular
smooth muscle.
The basic mechanism responsible for the intracellular
calcium concentration accumulation in vascular smooth
muscle during K-CP is related to membrane depolariza-
tion on the basis of Nernst’s equation of membrane
potential.19 Membrane depolarization promotes calcium
concentration influx through voltage-dependent calci-
um concentration channels. Calcium concentration in-
flux can also induce release of calcium concentration
from intracellular calcium concentration stores.20 In
addition, during surgical cardioplegic arrest, especially
with nonoxygenated crystalloid K-CP, coronary micro-
vessels are exposed to conditions of hypoxia. This
would be associated with a lower production of adeno-
sine triphosphate compared with a normoxic state. To
date, intracellular calcium concentration elevation with
hypoxia has been reported in many smooth muscles. In
previous studies, it was suggested that calcium concen-
tration release from the sarcoplasmic reticulum may
contribute to hypoxic pulmonary vasoconstriction.21,22
Thus it is tempting to speculate that hypoxic precondi-
tioning stimuli sensitizes calcium concentration efflux
mechanisms or minimizes calcium concentration influx
into vascular smooth muscle and thereby reduces vas-
cular contraction during and after hypoxic K-CP.
However, the exact mechanism by which precondition-
ing improves intracellular calcium concentration home-
ostasis against K-CP is not clear at this time and
requires further investigation.
Possible mechanism of vascular preconditioning
before K-CP. In the experiments presented here, pre-
treatment with KATP channel opener pinacidil signifi-
cantly reduced the K-CP–induced calcium concentra-
tion accumulation in smooth muscle and that was asso-
ciated with a significant attenuation of K-CP– induced
vascular contraction. One possible explanation for this
finding is that hyperpolarization of the smooth muscle
cell membrane as the result of the opening of KATP
channels can be expected to reduce the inward calcium
concentration current through voltage-sensitive calci-
um concentration channels23 and, consequently, to
maintain the intracellular calcium concentration level
during the subsequent period of sustained hypoxic K-
CP.
Another important finding presented in this study is
that agonist (U46619)-induced microvascular contrac-
tile responses after K-CP were significantly enhanced
in nonpreconditioned control vessels, whereas normal
contractility was preserved in hypoxic preconditioned
or pinacidil-pretreated vessels. The exact mechanisms
underlying post–K-CP vascular hypercontractility are
not clear; however, it may be related to the reduced cal-
cium concentration accumulation in the vascular
smooth muscle during K-CP. As shown in the nonpre-
conditioned control vessels, elevated intracellular cal-
cium concentration during K-CP may subsequently
stimulate activation of calcium concentration–depen-
dent intracellular signal pathways and may increase the
calcium concentration sensitivity of the contractile
apparatus after K-CP. Previous studies have demon-
strated that the agonist-induced vascular tone is regu-
lated by myosin light chain kinase, whose activity is
governed by a calcium concentration calmodulin-medi-
ated phosphorylation.24 There is some evidence that
intracellular calcium concentration may also directly
activate the calcium concentration-dependent isoforms
of protein kinase C (conventional protein kinase C) and
lead directly or indirectly to the phosphorylation of an
entirely different subset of cellular proteins including
caldesmon, a number of intermediate filament proteins
(desmin, synemin), and a few cytosolic proteins.25
Therefore it is reasonable to speculate that the intracel-
lular calcium concentration accumulation in microvas-
cular smooth muscle during K-CP becomes a strong
trigger for post–K-CP coronary hypercontractility.
Clinical implication and limitation of this study.
Myocardial preconditioning has been suggested to
have adjuvant cardioprotective effects with cardio-
plegic arrest and reperfusion.7,8 In addition, the
approach of pharmacologic preconditioning with KATP
channel openers may be of special interest because
these drugs are both clinically accessible and accept-
able. Several studies have indeed documented an
improved recovery of myocardial function treated with
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KATP channel openers given before or during a sus-
tained episode of global ischemia with or without car-
dioplegia.26-28 In the present study, we showed that
pharmacologic activation of KATP channels could atten-
uate vasoconstriction during and after K-CP, which
may improve not only the distribution of the cardio-
plegic solution during administration but also the coro-
nary microcirculation after reperfusion. Thus KATP
channel openers may have novel clinical applications
in achieving optimal myocardial protection for cardiac
surgical procedures.
The present study was designed to provide direct evi-
dence about beneficial effects of ischemic precondi-
tioning on coronary smooth muscle function. Although
the isolated coronary microvessel model used in the
present study has some advantages over an in vivo
preparation, we acknowledge some methodologic lim-
itations inherent in the experimental design, including
the hypoxic preconditioning as a simulation of
ischemic preconditioning. Furthermore, the results of
this study may be limited by the fact that they were
obtained under conditions of nonoxygenated crystal-
loid cardioplegia in normoxia. In light of these limita-
tions, the next logical step is to see whether the same
patterns of vascular responsiveness are observed under
cold and/or oxygenated cardioplegic conditions.
Conclusions 
Our experiments performed in an endothelium-
denuded isolated rat coronary microvessel model
demonstrated that preconditioning provides protective
effects on coronary microvascular function during and
after subsequent hypoxic K-CP by a mechanism that
regulates intracellular calcium concentration of vascu-
lar smooth muscle with activation of KATP channels.
The present study may suggest an important new
avenue to minimize the development of coronary
vasospasm, particularly in the setting of hyperkalemic
cardioplegic arrest under cardiac operations.
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